This clinical trial is focused on studying the effects of a medication called lutikizumab in adults with ulcerative colitis, a condition that causes inflammation and sores in the colon and rectum. The study will compare the safety and effectiveness of lutikizumab to another medication known as adalimumab, which is already used to treat this condition. Participants in the study will receive either lutikizumab, adalimumab, or a placebo, which is a substance with no active medication.
The purpose of the study is to evaluate how well lutikizumab works in reducing the symptoms of ulcerative colitis and to monitor any side effects. The study will involve both intravenous (IV) and subcutaneous (SC) forms of lutikizumab, meaning the medication will be administered either through a vein or under the skin. Participants will be monitored over a period of time to assess changes in their disease activity and any adverse events they may experience.
Throughout the study, participants will undergo regular assessments to track their progress. The study aims to determine the percentage of participants who show improvement in their condition by week 12. This includes looking at endoscopic improvement, which involves examining the inside of the colon, as well as clinical remission and response, which refer to the reduction or disappearance of symptoms. The study is expected to last for up to 52 weeks, providing valuable information on the long-term effects of lutikizumab in treating ulcerative colitis.
Austria 
Belgium 
Bulgaria 
Croatia 
Estonia 
France 
Germany 
Greece 
Hungary 
Ireland 
Italy 
Latvia 
Lithuania 
Norway 
Poland 
Slovenia 
Spain 
The Netherlands 